The principal constituent of cannabis, Δ9-tetrahydrocannabinol (THC), is moderately effective in treating nausea and vomiting, appetite loss, and acute and chronic pain. Oral THC (dronabinol) and the synthetic cannabinoid, nabilone, have been registered for medical use in the US and UK, but they have not been widely used because patients find it difficult to titrate doses of these drugs. Advocates for the medical use of cannabis argue that patients should be allowed to smoke cannabis to relieve these above-mentioned symptoms.
Some US state governments have legislated to allow the medical prescription of cannabis, but the US federal government has tried to prevent patients from obtaining cannabis and threatened physicians who prescribe it with criminal prosecution or loss of their licence to practise. In the UK and Australia, committees of inquiry have recommended medical prescription (UK) and exemption from criminal prosecution (New South Wales, Australia), but governments have not accepted these recommendations. The Canadian government allows an exemption from criminal prosecution to patients with specified medical conditions. It has recently legislated to provide cannabis on medical prescription to registered patients, but this scheme so far has not been implemented.
Some advocates argue that legalising cannabis is the only way to ensure that patients can use it for medical purposes. However, this would be contrary to international drug control treaties and is electorally unpopular. The best prospects for the medical use of cannabinoids lie in finding ways to deliver THC that do not involve smoking and in developing synthetic cannabinoids that produce therapeutic effects with a minimum of psychoactive effects. While awaiting these developments, patients with specified medical conditions could be given exemptions from criminal prosecution to grow cannabis for their own use, at their own risk.
Cannabis User Medical Purpose Criminal Prosecution Nabilone Dronabinol
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
The authors served respectively as Chair and Research Officer for the New South Wales Working Party on the Use of Cannabis for Medical Purposes. We thank the members of this group for improving our understanding of the scientific, regulatory and political issues raised by proposals to allow the medical use of cannabis. We thank Eva Congreve for help in locating literature, Heather Niven for helping to format the paper and Sarah Yeates for help in checking references.
The preparation of this work was supported by core funding for the National Drug and Alcohol Research Centre at the University of New South Wales from the Commonwealth Department of Health and Aged Care; funding from the NSW government for Louisa Degenhardt’s salary to prepare the Report of the Working Party on the Use of Cannabis for Medical Purposes; and by the Vice Chancellor’s Strategic Fund at the University of Queensland. The views expressed are those of the authors. There are no potential conflicts of interest other than the authors’ involvement with the NSW Working Group on the Use of Cannabis for Medical Purposes.
Grinspoon L, Bakalar J. Marihuana, the forbidden medicine. New Haven (CT): Yale University Press, 1993Google Scholar
Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC Press, 1986Google Scholar
Nahas G. Toxicology and pharmacology. In: Nahas G, editor. Marihuana in science and medicine. New York: Raven Press, 1984: 109–246Google Scholar
Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001; 6(2): 80–91PubMedGoogle Scholar
Mechoulam R, Hanu L. The cannabinoids: an overview: therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 2001; 6(2): 67–73PubMedGoogle Scholar
Iversen L. The science of marijuana. Oxford: Oxford University Press, 2000Google Scholar
Hall W, Degenhardt L, Lynskey M. The health and psychological consequences of cannabis use. Canberra (ACT): Australian Publishing Service, 2001Google Scholar
Goani Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 646–7CrossRefGoogle Scholar
Institute of Medicine. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press, 1999Google Scholar
Campbell FA, Tramer MR, Carrol D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323(7303): 13–6PubMedCrossRefGoogle Scholar
Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323(7303): 16–21PubMedCrossRefGoogle Scholar
Soderpalm AHV, Schuster A, de Wit H. Antiemetic effect of smoked marijuana: subjective and behavioural effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 2001; 69(3-4): 343–50PubMedCrossRefGoogle Scholar
Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10(2): 89–97PubMedCrossRefGoogle Scholar
Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14(1): 7–14PubMedCrossRefGoogle Scholar
Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21(8-9 Suppl.): 413S–6SPubMedGoogle Scholar
Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7(1): 39–50PubMedCrossRefGoogle Scholar
Smith PF. Cannabinoids in the treatment of pain and spasticity n multiple sclerosis. Curr Opin Investig Drugs 2002; 3(6): 859–64PubMedGoogle Scholar
Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58(9): 1404–7PubMedCrossRefGoogle Scholar
Romero J, Lasstres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological and therapeutic aspects. Pharmacol Ther 2002; 95(2): 137–52PubMedCrossRefGoogle Scholar
Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol (THC): a randomized cross-over trial. Pharmacopsychiatry 2002; 35: 57–61PubMedCrossRefGoogle Scholar
Swift W, Hall W. Tolerance, withdrawal and dependence. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potential. New York: Haworth, 2002: 257–68Google Scholar
Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001; 7(2): 43–61PubMedCrossRefGoogle Scholar